Clive A. Prestidge

Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs.

A silica-lipid hybrid (SLH) microcapsule system for oral delivery of poorly water-soluble drugs is reported for the first time. For the model drug celecoxib (CEL), SLH microcapsules composed of medium-chain triglycerides, lecithin and silica nanoparticles; with an internal porous matrix structure, were shown to offer several physicochemical and biopharmaceutical advantages in comparison with unmodified drug, lipid emulsion, dry emulsion and the commercial product, Celebrex. DSC and XRD analyses confirmed non-crystalline CEL in SLH microcapsules and verified medium term physical stability. Dissolution under sink conditions revealed a 2- to 5-fold increase in dissolution efficiencies (%DE) and significantly reduced t(50%) (> or =50-fold) for CEL formulated as SLH microcapsules. Orally dosed in vivo studies in rats demonstrated superior pharmacokinetics for SLH microcapsules. Specifically, the fasted-state bioavailability (F) was statistically higher (p<0.05) than for aqueous suspension, lipid solution, o/w emulsion and a maltodextrin-stabilised dry emulsion, and was greater than for Celebrex. SLHs showed the highest maximum plasma concentration (C(max)) among all tested formulations (p<0.05). Linear correlations were observed between %DE and the pharmacokinetic parameters (F and C(max)). It is postulated that SLH microcapsules improve CEL oral absorption via dissolution enhancement, potentially in conjunction with other unexplored mechanisms, hence offering the possibility of dose reduction for improved therapeutic efficacy and cost-effectiveness of poorly soluble drugs.

Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs.

Surface functionalized mesoporous silicon (pSi) microparticles are reported as a solid dispersion carrier for improving dissolution and enhancing the orally administered pharmacokinetics (fasted rat model) of indomethacin (IMC), employed as a model poorly soluble BCS type II drug. IMC was loaded via immersion/solvent evaporation onto the thermally oxidized pSi particles, which provide a stable hydrophilic matrix with a nanoporous structure. The solid state properties of IMC loaded pSi were characterized by Fourier transform infrared spectroscopy, X-ray powder diffraction, differential scanning calorimetry and thermogravimetric analysis. IMC molecules are encapsulated in a noncrystalline state due to geometric confinement in the nanopores; stability of the noncrystalline state has been demonstrated for several months under accelerated storage conditions. The pSi carrier facilitates accelerated immediate release of IMC and enhanced oral delivery performance in comparison with crystalline indomethacin and Indocid i.e. a 4-times reduction on T(max), a 200% increase on C(max) and a significant increase in bioavailability. The in vitro-in vivo correlation is discussed based on the noncompartment model and gives insight into the delivery mechanism for the pSi carrier.

Mesoporous silicon: a platform for the delivery of therapeutics

Nanostructuring materials can radically change their properties. Two interesting examples highlighted here are nanoscale porosity inducing biodegradability, and nanoscale confinement affecting the physical form of an entrapped drug. Mesoporous silicon is under increasing study for drug-delivery applications, and is the topic of this review. The authors focus on those properties of most relevance to this application, as well as those recent studies published on small molecule and peptide/protein delivery.

Silica nanoparticle coated liposomes: A new type of hybrid nanocapsule for proteins

A hybrid silica-liposome nanocapsule system containing insulin has been developed and the encapsulation, protection and release properties are evaluated. The formulation strategy is based on using insulin-loaded 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and cholesterol liposomes as a template for the deposition of inert silica nanoparticles. The influence of formulation and process variables on particle size, zeta potential and liposome entrapment of insulin is reported. The ability to protect against lipolytic degradation and sustain insulin release in vitro in simulated GI conditions is also reported. Depending on the concentration and charge ratio of liposomes and silica nanoparticles, nanoparticle coated liposomes with varied size and zeta potential were obtained with an insulin entrapment efficiency of 70%. The silica nanoparticle coating protected liposomes against degradation by digestive enzymes in vitro; the release rate of insulin from silica coated liposomes was reduced in comparison to uncoated liposomes. Thus the liposomal release kinetics and stability can be controlled by including a specifically engineered nanoparticle layer. Silica nanoparticle-liposomes hybrid nanocapsules show promise as a delivery vehicle for proteins and peptides.

Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38

SN38 (7-ethyl-10-hydroxy camptothecin) is a prominent and efficacious anticancer agent. It is poorly soluble in both water and pharmaceutically approved solvents; therefore, the direct formulation of SN38 in solution form is limited. Currently, the water soluble prodrug of SN38, irinotecan (CPT-11), is formulated as a low pH solution and is approved for chemotherapy. However, CPT-11, along with most other water-soluble prodrugs shows unpredictable inter-patient conversion to SN38 in vivo, instability in the physiological environment and variable dose-related toxicities. More recently, macromolecular prodrugs (i.e. EZN-2208, IMMU-130) and nanomedicine formulations (i.e. nanoemulsions, polymeric micelles, lipid nanocapsule/nanoparticle, and liposomes) of SN38 have been investigated for improved delivery to cancer cells and tissues. Specifically, these carriers can take advantage of the EPR effect to direct drug preferentially to tumour tissues, thereby substantially improving efficacy and minimising side effects. Furthermore, oral delivery has been shown to be possible in preclinical results using nanomedicine formulations (i.e. dendrimers, lipid nanocapsules, polymeric micelles). This review summarizes the recent advances for the delivery of SN38 with a focus on macromolecular prodrugs and nanomedicines.

Dry Hybrid Lipid−Silica Microcapsules Engineered from Submicron Lipid Droplets and Nanoparticles as a Novel Delivery System for Poorly Soluble Drugs

We report on the fabrication and characterization of dry hybrid lipid-silica nanoparticle based microcapsules with an internal porous matrix structure for encapsulation of poorly soluble drugs, and their delivery properties (in vitro release and lipolysis and in vivo pharmacokinetics demonstrated for indomethacin as a model drug). Microcapsules were prepared by spray drying of Pickering o/w emulsions containing either negatively or positively charged lipophilic surfactant in the oil phase and hydrophilic silica nanoparticles in the aqueous phase. Effective microcapsule formation is critically dependent on the interfacial structure of the nanoparticle containing emulsions, which are in turn controlled by the surfactant charge and the nanoparticle to lipid ratio. Microcapsules (containing 50-85% oil) can be prepared with 10 times fewer silica nanoparticles when a droplet-nanoparticle charge neutralizing mechanism is operative. Cross-sectional SEM imaging has confirmed the internal porous matrix structure and identified pore sizes in the range 20-100 nm, which is in agreement with BET average pore diameters determined from gas adsorption experiments. Differential scanning calorimetry and X-ray diffraction analysis have confirmed that the model drug indomethacin remains in a noncrystalline form during storage under accelerated conditions (40 degrees C, 75% RH). Dissolution studies revealed a 2-5-fold increase in dissolution efficiency and significantly reduced the time taken to achieve 50% of drug dissolution values (> or =2- or 10-fold) for indomethacin formulated as microcapsules in comparison to o/w submicron emulsions and pure drug, respectively. Orally dosed in vivo studies in rats have confirmed superior pharmacokinetics for the microcapsules. Specifically, the fasted state absolute bioavailability (F) was statistically higher (93.07 +/- 5.09%) (p < 0.05) than for aqueous suspension (53.54 +/- 2.91%) and o/w submicron emulsion (64.57 +/- 2.11%). The microcapsules also showed the highest maximum plasma concentration (C(max)) among the investigated formulations (p < 0.05). In vitro lipolysis showed statistically higher (p < 0.05) fasted digestion (75.8% after 5 min) and drug solubilization (98% after 5 min) in digestive products for microcapsules than o/w emulsions. The hybrid lipid-silica microcapsules improve oral absorption by enhancing lipolysis and drug dissolution.

Surface chemistry of porous silicon and implications for drug encapsulation and delivery applications

Porous silicon (pSi) has a number of unique properties that appoint it as a potential drug delivery vehicle; high loading capacity, controllable surface chemistry and structure, and controlled release properties. The native Si(y)SiH(x) terminated pSi surface is highly reactive and prone to spontaneous oxidation. Surface modification is used to stabilize the pSi surface but also to produce surfaces with desired drug delivery behavior, typically via oxidation, hydrosilylation or thermal carbonization. A number of advanced characterization techniques have been used to analyze pSi surface chemistry, including X-ray photoelectron spectroscopy and time of flight secondary ion mass spectrometry. Surface modification not only stabilizes the pSi surface but determines its charge, wettability and dissolution properties. Manipulation of these parameters can impact drug encapsulation by altering drug-pSi interactions. pSi has shown to be a successful vehicle for the delivery of poorly soluble drugs and protein therapeutics. Surface modification influences drug pore penetration, crystallinity, loading level and dissolution rate. Surface modification of pSi shows great potential for drug delivery applications by controlling pSi-drug interactions. Controlling these interactions allows specific drug release behaviors to be engineered to aid in the delivery of previously challenging therapeutics. Within this review, different pSi modification techniques will be outlined followed by a summary of how pSi surface modification has been used to improve drug encapsulation and delivery.

Water adsorption kinetics and contact angles of silica particles

Abstract Water adsorption was used to characterise the wettability of non-porous colloidal silica spheres with varying degrees of dehydration. In particular, water adsorption kinetics at saturated vapour pressure were correlated with advancing water contact angles determined by capillary penetration and the surface coverage of hydroxyl groups determined by diffuse reflectance infrared spectroscopy. Water uptake was found to be controlled by (1) the hydroxylation state of the silica particle surface and (2) the rate of water condensation to form multilayers. The processes that control water adsorption kinetics were fitted with first-order rate equations, thus enabling the concentration and reactivity of surface hydroxyl groups to be estimated. A Cassie approach was used to estimate the contact angle from water adsorption and infrared data; these were compared with contact angles determined by liquid penetration. A good correlation was observed between the hydroxylation-state of silica and the contact angle. An improved understanding of the interplay between surface chemistry, water adsorption and particle wettability has resulted.

Copper(II) activation and cyanide deactivation of zinc sulphide under mildly alkaline conditions

The adsorption of copper(II) ions onto zinc sulphide particles at pH 9 was determined by inductively coupled plasma atomic emission spectrophotometry and the resulting surfaces were characterised by X-ray photoelectron spectroscopy. The form of the copper(II) activated zinc sulphide surface is controlled by the copper(II) ion concentration and the activation time. Copper(II) activation, at an equivalent surface coverage of one monolayer, results in a copper-substituted zinc sulphide surface, whereas at surface coverages of ten or more equivalent copper(II) monolayers a copper(II) hydroxide surface phase covers the underlying copper-substituted zinc sulphide phases. Mechanisms are proposed which describe copper(II) activation in terms of precipitation, ion-exchange, redox and diffusion processes. Cyanide treatment removes copper hydroxide and copper-substituted species from the surfaces of copper(II) activated zinc sulphide. Ligand exchange mechanisms for cyanide deactivation of copper(II) activated zinc sulphide are proposed.

Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems

We investigate the role of hydrophilic fumed silica in controlling the digestion kinetics of lipid emulsions, hence further exploring the mechanisms behind the improved oral absorption of poorly soluble drugs promoted by silica-lipid hybrid (SLH) microcapsules. An in vitro lipolysis model was used to quantify the lipase-mediated digestion kinetics of a series of lipid vehicles formulated with caprylic/capric triglycerides: lipid solution, submicrometer lipid emulsions (in the presence and absence of silica), and SLH microcapsules. The importance of emulsification on lipid digestibility is evidenced by the significantly higher initial digestion rate constants for SLH microcapsules and lipid emulsions (>15-fold) in comparison with that of the lipid solution. Silica particles exerted an inhibitory effect on the digestion of submicrometer lipid emulsions regardless of their initial location, i.e., aqueous or lipid phases. This inhibitory effect, however, was not observed for SLH microcapsules. This highlights the importance of the matrix structure and porosity of the hybrid microcapsule system in enhancing lipid digestibility as compared to submicrometer lipid emulsions stabilized by silica. For each studied formulation, the digestion kinetics is well correlated to the corresponding in vivo plasma concentrations of a model drug, celecoxib, via multiple-point correlations (R(2) > 0.97). This supports the use of the lipid digestion model for predicting the in vivo outcome of an orally dosed lipid formulation. SLH microcapsules offer the potential to enhance the oral absorption of poorly soluble drugs via increased lipid digestibility in conjunction with improved drug dissolution/dispersion.